Idexx Laboratories price target raised to $540 from $510 at Stifel

Stifel raised the firm’s price target on Idexx Laboratories (IDXX) to $540 from $510 and keeps a Hold rating on the shares. The firm’s checks on Medical Technology & Supplies were “poor,” with deteriorating longitudinal metrics across several variables, the analyst tells investors in a research note. The firm thinks Idexx needs cancer diagnostics and inVue traction, as well as an improvement in visits.